United States Diabetic Gastroparesis Treatment Market 2026 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Global Diabetic Gastroparesis Treatment Market reached US$ 3.1 billion in 2022 and is expected to reach US$ 4.2 billion by 2030 growing with a CAGR of 3.8% during the forecast period 2023-2030.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/diabetic-gastroparesis-treatment-market?sb

Key Development:

United States: Recent Industry Developments

✅ In February 2026, CinDome Pharma continued clinical development of CIN-102 (deudomperidone) for gastroparesis, expanding studies evaluating symptom reduction in adults with moderate to severe disease. The program focuses on improving gastric motility with fewer neurological side effects. The trial supports development of safer prokinetic therapies for diabetic gastroparesis.

✅ In January 2026, Aclipse Therapeutics advanced development of M107, a disease-modifying therapy targeting inflammation involved in gastroparesis progression. The drug aims to treat the underlying nerve and muscle dysfunction rather than only symptoms. The program represents a next-generation approach for chronic diabetic gastroparesis management.

✅ In December 2025, Evoke Pharma strengthened commercialization of GIMOTI nasal spray for diabetic gastroparesis, expanding use of non-oral metoclopramide therapy for patients with delayed gastric emptying. The formulation improves drug absorption compared with tablets. It supports improved symptom control in patients with recurrent nausea and vomiting.

✅ In March 2024, Renexxion received U.S. FDA clearance for the investigational drug naronapride to enter clinical studies for gastroparesis treatment. The therapy is designed to enhance gastrointestinal motility through selective receptor activity. The approval enabled expansion of clinical trials in the United States for patients with severe symptoms.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=diabetic-gastroparesis-treatment-market

Japan: Recent Industry Developments

✅ In March 2026, Japanese researchers expanded clinical evaluation of acotiamide-based prokinetic therapy for gastric motility disorders, including diabetic gastroparesis-related symptoms. The drug enhances acetylcholine release to improve stomach emptying. The development supports Japan's focus on advanced gastrointestinal motility treatments.

✅ In February 2026, pharmaceutical companies in Japan increased R&D efforts in prokinetic and neuromodulation therapies for chronic gastric motility disorders caused by diabetes complications. The programs focus on improving long-term safety and effectiveness compared with older dopamine-blocking drugs. The initiative reflects growing demand for innovative gastroparesis treatments.

✅ In January 2026, academic-industry collaborations in Japan accelerated development of next-generation gastrointestinal drugs targeting delayed gastric emptying and autonomic nerve dysfunction. These programs include receptor-selective prokinetic compounds and combination therapies. The research aims to provide safer options for diabetic gastroparesis patients.

✅ In October 2025, Japanese clinical research groups participated in global studies evaluating emerging gastroparesis therapies developed by international biotech companies. The trials focus on improving nausea control, gastric motility, and quality of life in diabetic patients. The collaboration strengthens Japan's role in global gastrointestinal drug development.

Key Players:

=> EVOKE PHARMA, ANI Pharmaceuticals, Inc., Janssen Pharmaceutica N.V, Teva Pharmaceuticals Inc., Pfizer Inc., Salix Pharmaceuticals, Inc., Allergan, Novartis AG, SCHWITZ BIOTECH, Wellona Pharma, and among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/diabetic-gastroparesis-treatment-market?sb

Growth Forecast Projected:

The Global Diabetic Gastroparesis Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Diabetic Gastroparesis Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Key Segments:

➥ By Type: Grade 2, Grade 3

➥ By Drug Class: Gastroprokinetic Agents, Antiemetic Agents, Anti-histamines, Others

➥ By Route of Administration: Oral, Parenteral, Nasal

➥ By Distribution Channel: Hospitals, Retail Pharmacies, Online Pharmacies

➥ By Region: North America, Europe, South America, Asia Pacific, Middle East, Africa - Share, Size, Outlook, and Opportunity Analysis (2025-2033)

Regional Analysis for Diabetic Gastroparesis Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Diabetic Gastroparesis Treatment producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Diabetic Gastroparesis Treatment revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

FAQ

What is the current size of the Diabetic Gastroparesis Treatment Market?

A: In 2022, the Diabetic Gastroparesis Treatment Market was valued at US$ 3.1 billion, reflecting its strong industry presence.

Q2: How large is the Diabetic Gastroparesis Treatment Market expected to be by 2030?

A: By 2030, industry forecasts suggest the Diabetic Gastroparesis Treatment Market will grow to around US$ 4.2 billion , demonstrating significant expansion.

Q3: What is the growth rate of the Diabetic Gastroparesis Treatment Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 3.8% during the forecast period from 2023 to 2030.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.